Immune modulator therapy for microscopic colitis in a case series of 73 patients.

Thomas Gerard CotterA K KambojS B HicksW J TremaineE V LoftusD S Pardi

Published in: Alimentary pharmacology & therapeutics (2017)

The majority of patients with active MC responded to thiopurines, methotrexate, or anti-TNF therapy. Larger controlled studies are required to confirm the efficacy and safety of these medications in MC.

Keyphrases

end stage renal disease
ejection fraction
chronic kidney disease
newly diagnosed
rheumatoid arthritis
prognostic factors
high dose
stem cells
patient reported outcomes
low dose
mesenchymal stem cells
cell therapy
case control
smoking cessation